ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Evidence strongly supports the takeover is Libigel related and that Roth Capital is most likely the financial adviser they have been working with. It most likely started at the time of the meetings with Roth Capital Management in September, 2016. By the time of the meeting:

-The first of three new Libigel related patent applications had been filed
-The Libigel trademark had been allowed to expire without a replacement name being applied for.
- The following month the other two Libigel related patent applications were filed. (All replacing the existing three patent applications)
- I don't know the exact time they removed Libigel as a Licensing opportunity from the Deals.bio website, but I am willing to bet it was around September 2016.

ANI Pharmaceuticals considering sale after receiving interest, Bloomberg says ANI Pharmaceuticals is looking into a sale after drawing takeover interest, Bloomberg reports, citing people familiar with the matter. The company is working with a financial adviser to weigh options for the business, which has attracted interest from private equity firms and other pharmaceutical companies, the report says. Sale considerations are at a preliminary stage and a formal sale process may begin in the next few weeks, the report notes.

The Fly Takeover-Bloomberg report

ANI Pharmaceuticals management to meet with Roth Capital Meetings to be held in Boston on September 27 and in New York on September 28 hosted by Roth Capital.

The Fly- reporting Roth Meetings

Since the meetings with Roth ANIP has had only one Investor conference presentation and may have been scheduled to address the fact that it was pointed out that they may be in quiet mode as they had not done a conference in over 14 months.